Animation - TIL Cell Therapy for Melanoma
Please note: This animation is currently being updated to reflect the February 2024 FDA approval of this therapy. Please continue to explore the website, and check back for this updated animation soon.
This animation provides an overview of Tumor Infiltrating Lymphocyte (TIL) Cell Therapy for melanoma. TIL Cell Therapy is a new type of immunotherapy that utilizes TILs to attack cancer cells. On February 16, 2024, the FDA approved AMTAGVI, the first cellular therapy indicated for the treatment of adult patients with cutaneous melanoma that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic). AMTAGVI is a tumor-derived autologous T cell immunotherapy composed of a patient's own T cells, a type of cell that helps the immune system fight cancer. Watch to learn how TIL Cell Therapy is prepared in the lab, how the infusion works, its effectiveness, possible side effects, and its current use in melanoma clinical trials. You may want to ask your doctor if TIL Cell Therapy could be an option for you.
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about melanoma which will help other patients, caregivers and families.
Animation - TIL Cell Therapy for Melanoma
Slide Show - TIL Cell Therapy for Melanoma
1.
Who is eligible for TIL therapy? What are the criteria?
2.
Why is TIL therapy effective to treat melanoma?
3.
What happens to my tumor sample after the biopsy?
4.
Why do I need chemotherapy to prepare for the TIL therapy?
5.
What side effects can I expect after receiving chemotherapy to prepare for the TIL infusion?
6.
What side effects can I expect after the TIL cells are infused back into me?
7.
How will I know if my melanoma has responded to TIL therapy?
8.
Why might TIL therapy not be recommended for me?
